학술논문
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Document Type
Article
Author
Source
In Leukemia Research June 2023 129
Subject
Language
ISSN
0145-2126